Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies

Nature Biotechnology

Volumn 31, Issue 8, 2013, Pages 753-758

  Spiess, Christoph ^a   Merchant, Mark ^a   Huang, Arthur ^a,b   Zheng, Zhong ^a   Yang, Nai Ying ^a   Peng, Jing ^a   Ellerman, Diego ^a   Shatz, Whitney ^a   Reilly, Dorothea ^a   Yansura, Daniel G ^a   Scheer, Justin M ^a  

^a GENENTECH INC   (United States)

^b RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL SIGNALING;

BACTERIAL STRAINS; HALF-ANTIBODIES; HEAVY AND LIGHT CHAINS; NATURAL ARCHITECTURE; POTENTIAL UTILITY; PRODUCTION STRATEGY; RAPID GENERATIONS; RECEPTOR TYROSINE KINASE;

ANTIBODIES;

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE;

ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ARTICLE; BACTERIUM CULTURE; CELL GROWTH; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TUMOR GROWTH;

BACTERIA (MICROORGANISMS);

ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; BACTERIA; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; IMMUNOGLOBULIN G; NEOPLASMS; PROTEIN ENGINEERING; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84881460836     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2621     Document Type: Article

References (30)

1. Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974-977 (2008).
2. Yu, Y.J. et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3, 84ra44 (2011).
3. Chelius, D. et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2, 309-319 (2010).
4. Wu, C. et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 1, 339-347 (2009).
5. Wu, C. et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25, 1290-1297 (2007).
6. Bostrom, J. et al. Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009).
7. Schaefer, G. et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472-486 (2011).
8. Ridgway, J.B., Presta, L.G. & Carter, P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-621 (1996).
9. Atwell, S., Ridgway, J.B., Wells, J.A. & Carter, P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 270, 26-35 (1997).
10. Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637-19646 (2010).
11. Davis, J.H. et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 23, 195-202 (2010).
12. Schaefer, W. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA 108, 11187-11192 (2011).
13. Merchant, A.M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677-681 (1998).
14. Jackman, J. et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J. Biol. Chem. 285, 20850-20859 (2010).
15. Labrijn, A.F. et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 27, 767-771 (2009).
16. Strop, P. et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J. Mol. Biol. 420, 204-219 (2012).
17. Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl. Acad. Sci. USA 105, 692-697 (2008).
18. Xu, H. et al. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin. Cancer Res. 17, 4425-4438 (2011).
19. Engelman, J.A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007).
20. Turke, A.B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77-88 (2010).
21. Zhang, Y.-W. et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-6890 (2010).
22. Jin, H. et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-4368 (2008).
23. Feige, M.J., Hendershot, L.M. & Buchner, J. How antibodies fold. Trends Biochem. Sci. 35, 189-198 (2010).
24. Simmons, L.C. et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods 263, 133-147 (2002).
25. Mazor, Y., Van Blarcom, T., Mabry, R., Iverson, B.L. & Georgiou, G. Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat. Biotechnol. 25, 563-565 (2007).
26. Baumal, R., Potter, M. & Scharff, M.D. Synthesis, assembly, and secretion of gamma globulin by mouse myeloma cells. 3. Assembly of the three subclasses of IgG. J. Exp. Med. 134, 1316-1334 (1971).
27. Zhang, Y.-W. et al. Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-106 (2005).
28. Makino, T., Skretas, G., Kang, T.H. & Georgiou, G. Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies. Metab. Eng. 13, 241-251 (2011).
29. Chan, C.E.Z., Lim, A.P.C., Chan, A.H.Y., MacAry, P.A. & Hanson, B.J. Optimized expression of full-length IgG1 antibody in a common E. coli strain. PLoS ONE 5, e10261 (2010).
30. Reilly, D.E. & Yansura, D.G. Production of antibodies and antibody fragments in Escherichia coli. in Antibody Engineering (eds. Kontermann, R. & Dübel, S.) 331-344 (Springer Berlin Heidelberg, 2010).